Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vididencel in Chronic Phase CML Patients With Measurable Residual Disease
NCT07651878Phase 1Recruiting
- Sponsor
- Mendus
- Start
- Apr 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vididencel in chronic myeloid leukemia (CML), sponsored by Mendus. Primary endpoint: Safety and Tolerability of Vididencel. Started Apr 2026; status: recruiting.
02
Drugs
vididencel
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07651878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07651878.